Physician profile
Robert P Kaplan
NPI 1124101035
$7,698.27
in general payments reported to CMS, 2019-2025
45 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,257 · 2020: $1,569 · 2021: $1,099 · 2022: $1,264 · 2023: $763 · 2024: $1,251 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,509.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,065.57 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals Lp | $871.48 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $564.07 | 2021-2024 | |
| Amarin Pharma, INC. | $544.09 | 2019-2022 | |
| Glaxosmithkline, LLC. | $510.78 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Allergan, INC. | $464.35 | 2020 | |
| Sanofi-Aventis U.S. LLC | $453.72 | 2019-2023 | |
| Novo Nordisk INC | $414.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $383.09 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $313.69 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $295.44 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $231.12 | 2019-2021 | |
| Livanova USA, INC. | $209.08 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.92 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.60 | 2019-2024 | Jardiance |
Show all 40 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.